Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $1.6 million.

  • Lineage Cell Therapeutics' Prepaid Assets rose 2817.12% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 2817.12%. This contributed to the annual value of $2.6 million for FY2024, which is 1588.02% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Prepaid Assets stood at $1.6 million for Q3 2025, which was up 2817.12% from $1.3 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' Prepaid Assets' 5-year high stood at $3.2 million during Q3 2021, with a 5-year trough of $1.3 million in Q3 2024.
  • Over the past 5 years, Lineage Cell Therapeutics' median Prepaid Assets value was $1.9 million (recorded in 2025), while the average stood at $2.0 million.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Prepaid Assets skyrocketed by 12355.02% in 2021 and then tumbled by 4854.29% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Prepaid Assets (Quarter) stood at $2.4 million in 2021, then decreased by 22.25% to $1.8 million in 2022, then rose by 20.57% to $2.2 million in 2023, then grew by 15.88% to $2.6 million in 2024, then tumbled by 35.51% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, $1.3 million for Q2 2025, and $1.9 million during Q1 2025.